HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (1- methyl- 1H- indol- 3- yl)- 4- (1- methyl- 6- nitro- 1H- indol- 3- yl)- 1H-pyrrole-2,5-dione

structure in first source

Also Known As:

1H-pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)-; Ro 31-7453

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 3-(1-methyl-1H-indol-3-yl)-4-(1-methyl-6-nitro-1H-indol-3-yl)- 1H-pyrrole-2,5-dione: 3

Experts

1.	Breimer, Lars: 2 articles (08/2004 - 07/2004)
2.	DeMario, Mark: 2 articles (08/2004 - 07/2004)
3.	Gao, Mingzhang: 1 article (10/2010)
4.	Hutchins, Gary D: 1 article (10/2010)
5.	Miller, Kathy D: 1 article (10/2010)
6.	Sledge, George W: 1 article (10/2010)
7.	Wang, Min: 1 article (10/2010)
8.	Zheng, Qi-Huang: 1 article (10/2010)
9.	Aghajanian, Carol: 1 article (08/2004)
10.	Bienvenu, Bryan: 1 article (08/2004)

Related Diseases

1.

Neoplasms (Cancer)

08/15/2004 - "Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors."
10/01/2010 - "[(11)C]MKC-1 ([(11)C]Ro 31-7453) was first designed and synthesized as a new potential positron emission tomography cancer imaging agent through two different strategies. "
10/01/2010 - "The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent."
08/15/2004 - "Using an accelerated dose-escalation schedule, 48 patients with advanced solid tumors were treated with doses of Ro 31-7453 ranging from 25 to 800 mg/m(2)/d given for 4 consecutive days, every 3 weeks. "
07/01/2004 - "A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors."

Related Drugs and Biologics

1.	A 7 (A-7)